tetano
Editor, Senior Moderator
Cureus
. 2020 Jun 26;12(6):e8845.
doi: 10.7759/cureus.8845.
Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts
Karun Neupane[SUP] 1 [/SUP], Zahoor Ahmed[SUP] 2 [/SUP], Hira Pervez[SUP] 3 [/SUP], Rabia Ashraf[SUP] 4 [/SUP], Aneela Majeed[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.
Keywords: coronavirus; covid-19; hydroxychloroquine; remdesivir; sars-cov-2; therapeutics; treatment.
. 2020 Jun 26;12(6):e8845.
doi: 10.7759/cureus.8845.
Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts
Karun Neupane[SUP] 1 [/SUP], Zahoor Ahmed[SUP] 2 [/SUP], Hira Pervez[SUP] 3 [/SUP], Rabia Ashraf[SUP] 4 [/SUP], Aneela Majeed[SUP] 5 [/SUP]
Affiliations
- PMID: 32754388
- PMCID: PMC7386097
- DOI: 10.7759/cureus.8845
Abstract
Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.
Keywords: coronavirus; covid-19; hydroxychloroquine; remdesivir; sars-cov-2; therapeutics; treatment.